Neurophet Partners With RapidAI on Brain Imaging
The collaboration integrates Neurophet's AI brain imaging solutions into RapidAI's Rapid Enterprise Platform for clinicians.
Updated on Nov. 2, 2026 in Alzheimer’s
Live Poll
Would you trust a doctor who used AI to read your brain scan?
Neurophet, a Seoul-based artificial intelligence company focused on brain disorder diagnosis and treatment, has partnered with RapidAI to integrate its brain imaging solutions into the Rapid Enterprise Platform. The partnership is expected to accelerate commercialization of Neurophet's solutions in the U.S. market.
Why it matters
Imaging findings are important for monitoring potential treatment-related side effects in patients receiving anti-amyloid Alzheimer's therapies. The partnership aims to give clinicians access to advanced neuroimaging within existing workflows.
The partnership links Neurophet's AQUA AD Plus tool, which uses AI-powered MRI analysis to quantify brain lesions, with a RapidAI network of more than 2,500 hospitals across 100 countries. Terms of the agreement and the pace of U.S. rollout have not been disclosed.
The players
Neurophet
A South Korean artificial intelligence company founded in 2016 that develops brain imaging tools for diagnosing and treating brain disorders.
RapidAI
A global enterprise clinical AI company whose platform is used by more than 2,500 hospitals across 100 countries.
The details
Neurophet AQUA AD Plus identifies and quantifies hypointense and hyperintense lesions on brain MRI and is designed to support prescribing decisions for Alzheimer's treatments. Radiologists will access results through Rapid Navigator Pro, and clinicians through the Rapid Mobile App, while Neurophet plans full-scale distribution of AQUA AD Plus to U.S. memory disorders centers.
Timeline
Neurophet was founded in 2016.
The partnership with RapidAI was announced on November 2, 2026.
Roadmap
Anti-amyloid therapies have made MRI-based safety monitoring a practical requirement for Alzheimer's care, shifting demand toward automated brain imaging tools. This partnership positions Neurophet's AI analysis inside a large clinical AI platform as hospitals look for scalable ways to meet that monitoring need.
Patients receiving anti-amyloid Alzheimer's treatments may have brain MRI scans monitored for side effects using these tools. Access will depend on whether their clinic or memory disorders center adopts the platform.
The takeaway
Clinicians treating patients with Alzheimer's therapies should watch for integrated AI imaging tools that make safety monitoring easier to fit into existing radiology workflows. Access will vary by hospital and region as commercialization proceeds.
Further reading
Explore more coverage in the Alzheimer’s section.
Live Poll
Would you trust a doctor who used AI to read your brain scan?
